These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37093531)

  • 1. Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer.
    Pu W; Wang F; Li K; Xing C; Zhuang Z; Wang H; Bian H; Zhang R; Xiao L
    Appl Biochem Biotechnol; 2023 Dec; 195(12):7821-7831. PubMed ID: 37093531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
    Zeng Q; Xie L; Zhou N; Liu M; Song X
    Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
    Li WM; Hu TT; Zhou LL; Feng YM; Wang YY; Fang J
    BMC Cancer; 2016 Jul; 16():454. PubMed ID: 27405731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.
    Allouchery V; Perdrix A; Calbrix C; Berghian A; Lequesne J; Fontanilles M; Leheurteur M; Etancelin P; Sarafan-Vasseur N; Di Fiore F; Clatot F
    Sci Rep; 2021 Dec; 11(1):24041. PubMed ID: 34911971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
    Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Liquid Biopsy to Detect PIK3CA Mutation in Metastatic Breast Cancer.
    Nakai M; Yamada T; Sekiya K; Sato A; Hankyo M; Kuriyama S; Takahashi G; Kurita T; Yanagihara K; Yoshida H; Ohashi R; Takei H
    J Nippon Med Sch; 2022 Mar; 89(1):66-71. PubMed ID: 33692304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplexed assays for detection of mutations in PIK3CA.
    Board RE; Thelwell NJ; Ravetto PF; Little S; Ranson M; Dive C; Hughes A; Whitcombe D
    Clin Chem; 2008 Apr; 54(4):757-60. PubMed ID: 18375489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
    Qiu W; Tong GX; Manolidis S; Close LG; Assaad AM; Su GH
    Int J Cancer; 2008 Mar; 122(5):1189-94. PubMed ID: 17990317
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
    Alvarez-Garcia V; Bartos C; Keraite I; Trivedi U; Brennan PM; Kersaudy-Kerhoas M; Gharbi K; Oikonomidou O; Leslie NR
    Sci Rep; 2018 Mar; 8(1):4290. PubMed ID: 29523855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.
    Sayagués JM; Montero JC; Jiménez-Pérez A; Del Carmen S; Rodríguez M; Vidal Tocino R; Montero E; Sanz J; Abad M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.